New, more effective, and less toxic therapies have revolutionized the management of multiple myeloma in the past decade. Triple therapy with proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies is now the standard treatment. Despite the availability of new treatments, most patients will develop refractory disease to the therapies that currently comprise the standard of care.
|Number of pages||6|
|Journal||Journal of Managed Care Medicine|
|State||Published - 2022|